[Don Quijote de la Mancha]

Fuente de ingreso: Luis Bardón Mesa. Fecha de ingreso: jun. 1998.Sign.: [ ]3, A-Z4, 2A-2T4, 2V5Grab. en epigrafes y fin de la tablaFront.: "D. Pedro Arenal, arquitecto, lo invento y lo dibujo", "D. Juan de la Cruz Geografo de S. M. lo grabó"Las h. de grab.: Antonio Carnicero, y Gregorio Ferro dibujantes y Joaquin Ballester, Francisco Muntaner, J. Joaquin Fabregat, Fernando Selma grabadores

Formación curricular en diseño para todas las personas en pedagogía = Training curriculum in design for all in pedagogy

227 p.La universidad ejerce un papel fundamental en la configuración de la sociedad en la que vivimos. Entre sus compromisos se encuentra la obligación de establecer las bases para la construcción de un entorno más diverso, accesible e inclusivo, en el que tengan cabida todas las personas, independientemente de su condición física, procedencia o entorno social, entre otras opciones. En el contexto de construir un entorno más inclusivo, se inició nuestra colaboración con el proyecto “Formación Curricular en Diseño para Todas las Personas”, una iniciativa surgida a partir de la presentación del Libro Blanco del Diseño para Todos en la Universidad (2006), elaborado por la Coordinadora del Diseño para Todas las Personas, con la colaboración de la Fundación ONCE y el Instituto de Mayores y Servicios Sociales (IMSERSO), y que supuso el punto de partida para la introducción de los conceptos básicos del Diseño para Todos (D4ALL) y la Accesibilidad Universal en los currículos formativos de los estudios universitario

Retratos de españoles ilustres : con un epitome de sus vidas.

Els artistas són: Leonardo da Vinci, Bartolomé Vázquez, José del Castillo, Francisco Muntaner, Rafael Gimeno, F. Selma, J.A. Carmona, Esteve, M. Brandi, Manuel de la Cruz, J. Jimeno, Ticiano, Ballester, A. Carnicero, J. Barcelon, J. Maea, D.J. Ferro, Ranch, Josef Beraton, Francisco de Paula Marti, F. Ramos, S. Brieva, José Camarón, M. Gamborino, Salesa, M.S. Carmona, Blas Ametller, Luis Fernández Noseret, José López Enguídanos, Navia, M. Alegre, J.R. Rodríguez, Alonso Sánchez Coello, Tomás López Enguídanos, Vicente López Enguídanos, Anton van Dyck, N.B., Pantoja, V. Mariani, M. Esquivel, Manuel Eraso, F. Ribera, Juan Brunete, Manuel Albuerne, N. Besanzon, Alonso García Sanz, Juan Alonso, Esteban BoixN. B. podría corresponder a Nicolás Barsanti, o a Nicolás Besanzón, segons B.N.E. [12-06-2009Retrats calc. en f. de làmEsc. reial calc. de Carles IV d'Espanya a portText a 1 co

36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE

Background: Venous thromboembolism (VTE), encompassing both deep vein thrombosis (DVT) and pulmonary embolism (PE), is a leading cause of morbidity and mortality worldwide.Methods: GARFIELD-VTE is a prospective, non-interventional observational study of real-world treatment practices. We aimed to capture the 36-month clinical outcomes of 10,679 patients with objectively confirmed VTE enrolled between May 2014 and January 2017 from 415 sites in 28 countries.Findings: A total of 6582 (61.6 %) patients had DVT alone, 4097 (38.4 %) had PE +/- DVT. At baseline, 98.1 % of patients received anticoagulation (AC) with or without other modalities of therapy. The proportion of patients on AC therapy decreased over time: 87.6 % at 3 months, 73.0 % at 6 months, 54.2 % at 12 months and 42.0 % at 36 months. At 12-months follow-up, the incidences (95 % confidence interval [CI]) of all-cause mortality, recurrent VTE and major bleeding were 6.5 (7.0-8.1), 5.4 (4.9-5.9) and 2.7 (2.4-3.0) per 100 person-years, respectively. At 36-months, these decreased to 4.4 (4.2-4.7), 3.5 (3.2-2.7) and 1.4 (1.3-1.6) per 100 person-years, respectively. Over 36-months, the rate of all-cause mortality and major bleeds were highest in patients treated with parenteral therapy (PAR) versus oral anti-coagulants (OAC) and no OAC, and the rate of recurrent VTE was highest in patients on no OAC versus those on PAR and OAC. The most frequent cause of death after 36-month follow-up was cancer (n = 565, 48.6 %), followed by cardiac (n = 94, 8.1 %), and VTE (n = 38, 3.2 %). Most recurrent VTE events were DVT alone (n = 564, 63.3 %), with the remainder PE, (n = 236, 27.3 %), or PE in combination with DVT (n = 63, 7.3 %).Interpretation: GARFIELD-VTE provides a global perspective of anticoagulation patterns and highlights the accumulation of events within the first 12 months after diagnosis. These findings may help identify treatment gaps for subsequent interventions to improve patient outcomes in this patient population

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI) : a phase 3, placebo-controlled, randomised trial

Background: Patients with stable coronary artery disease and diabetes with previous percutaneous coronary intervention (PCI), particularly those with previous stenting, are at high risk of ischaemic events. These patients are generally treated with aspirin. In this trial, we aimed to investigate if these patients would benefit from treatment with aspirin plus ticagrelor. Methods: The Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) was a phase 3 randomised, double-blinded, placebo-controlled trial, done in 1315 sites in 42 countries. Patients were eligible if 50 years or older, with type 2 diabetes, receiving anti-hyperglycaemic drugs for at least 6 months, with stable coronary artery disease, and one of three other mutually non-exclusive criteria: a history of previous PCI or of coronary artery bypass grafting, or documentation of angiographic stenosis of 50% or more in at least one coronary artery. Eligible patients were randomly assigned (1:1) to either ticagrelor or placebo, by use of an interactive voice-response or web-response system. The THEMIS-PCI trial comprised a prespecified subgroup of patients with previous PCI. The primary efficacy outcome was a composite of cardiovascular death, myocardial infarction, or stroke (measured in the intention-to-treat population). Findings: Between Feb 17, 2014, and May 24, 2016, 11 154 patients (58% of the overall THEMIS trial) with a history of previous PCI were enrolled in the THEMIS-PCI trial. Median follow-up was 3·3 years (IQR 2·8–3·8). In the previous PCI group, fewer patients receiving ticagrelor had a primary efficacy outcome event than in the placebo group (404 [7·3%] of 5558 vs 480 [8·6%] of 5596; HR 0·85 [95% CI 0·74–0·97], p=0·013). The same effect was not observed in patients without PCI (p=0·76, p interaction=0·16). The proportion of patients with cardiovascular death was similar in both treatment groups (174 [3·1%] with ticagrelor vs 183 (3·3%) with placebo; HR 0·96 [95% CI 0·78–1·18], p=0·68), as well as all-cause death (282 [5·1%] vs 323 [5·8%]; 0·88 [0·75–1·03], p=0·11). TIMI major bleeding occurred in 111 (2·0%) of 5536 patients receiving ticagrelor and 62 (1·1%) of 5564 patients receiving placebo (HR 2·03 [95% CI 1·48–2·76], p<0·0001), and fatal bleeding in 6 (0·1%) of 5536 patients with ticagrelor and 6 (0·1%) of 5564 with placebo (1·13 [0·36–3·50], p=0·83). Intracranial haemorrhage occurred in 33 (0·6%) and 31 (0·6%) patients (1·21 [0·74–1·97], p=0·45). Ticagrelor improved net clinical benefit: 519/5558 (9·3%) versus 617/5596 (11·0%), HR=0·85, 95% CI 0·75–0·95, p=0·005, in contrast to patients without PCI where it did not, p interaction=0·012. Benefit was present irrespective of time from most recent PCI. Interpretation: In patients with diabetes, stable coronary artery disease, and previous PCI, ticagrelor added to aspirin reduced cardiovascular death, myocardial infarction, and stroke, although with increased major bleeding. In that large, easily identified population, ticagrelor provided a favourable net clinical benefit (more than in patients without history of PCI). This effect shows that long-term therapy with ticagrelor in addition to aspirin should be considered in patients with diabetes and a history of PCI who have tolerated antiplatelet therapy, have high ischaemic risk, and low bleeding risk